Clinical Trial Participant Payments: Why Are Participants Still Waiting?

A clinical trial can approve the right payment amount, document it correctly, and still make participants wait days or weeks to use the money they have already earned.

That is the operational gap sponsors and CROs need to measure.

The delay often doesn’t start with the payment rail. It starts earlier, when a completed visit still needs verification, an expense review, an approval routing, or information re-entered between disconnected systems. By the time the payout moves, the participant may have already spent money on gas, parking, meals, childcare, or travel and waited days for reimbursement.

Clinical trial participant payments should be measured from eligible activity to usable funds, not from payment initiation to settlement.

That distinction changes the question from “How much do we pay participants?” to “How well does the payment process work once they have earned it?” For sponsors and CROs, the answer affects participant burden, site workload, exception volume, and the real performance of the payment workflow.

Key Takeaways

• Measure payment time from a completed visit or incurred expense to usable funds, so upstream approval delays show up in the data.
• Separate compensation from reimbursement in workflows and reporting, since each carries different review steps.
• Map every manual handoff between the visit record and payment initiation to find where days are lost.
• Offer participants payment methods that fit their banking access and local market.
• Design exception handling before launch so failed payments get resolved without the coordinator acting as a help desk.

Compensation and Reimbursement Are Different Obligations

Research participant compensation recognizes time, effort, inconvenience, and study-related burden. Clinical trial reimbursement repays out-of-pocket expenses the participant incurred to take part, such as mileage, airfare, hotels, parking, and meals.

FDA’s guidance on payment and reimbursement to research subjects states that the agency “does not consider reimbursement for travel expenses to and from the clinical trial site and associated costs such as airfare, parking, and lodging to raise issues regarding undue influence.” Payment for participation receives closer IRB scrutiny, because the amount could sway a decision to enroll or stay.

Both share a timing principle. FDA says payment credit “should accrue as the study progresses and not be contingent upon the subject completing the entire study.” The NIH Office of Human Subjects Research Protections recommends providing compensation over time as participants complete study activities. It also asks investigators to include “the amount, method, timing, and purpose of payment” in both the protocol and the consent form.

Timing and method are already part of a study’s ethical design. The operational question is whether the payment process delivers the timing the consent form implies.

When Participants Float the Cost of Participating

Reimbursement repays a cost. It does nothing to address when the participant has to pay.

A participant who drives two hours each way has paid for gas, parking, a meal, and possibly childcare before any reimbursement arrives. If the study reimburses three weeks later, the participant has extended three weeks of credit to the trial. For a participant on a tight monthly budget, carrying those costs can make the next visit harder to absorb.

Research is starting to document what these costs look like. A 2026 mixed-methods pilot in JNCI Cancer Spectrum provided monthly reimbursement for trial participation costs to 33 women with breast cancer.

Participants reported using it for food (96%), transportation (89%), caregiving (68%), and medical costs (64%). The share who reported borrowing money fell from 36% to 21% over four months. One participant said that knowing the trial “wasn’t going to place a financial strain on us” made it “easier for me to feel good about continuing.”

The authors call it a small, single-site pilot, so it does not establish a general effect. It does show the costs participants carry and that they link financial strain to staying in a study.

The reimbursement process adds its own work: keep receipts, submit them, wait for approval, check whether funds arrived, and call the site if they haven’t. On top of a demanding protocol, that is one more thing to manage.

Where Clinical Trial Payments Actually Stall

From the participant’s side, a payment moves through a chain like this:

Eligible activity completed → activity verified → expenses submitted → receipts reviewed → payment approved → payment initiated → payment delivered → funds usable

Payment discussions tend to focus on the last three steps. Many participant card programs can load funds within minutes of approval. The operative words are of approval. A payment can load in minutes and still reach the participant a week after the visit if everything before approval took six days.

The usual causes of delay sit upstream of the payment rail:

• Manual visit verification. A coordinator confirms the payment-triggering activity occurred, often by checking a separate system.
• Manual payment initiation. Someone enters or releases the payment, usually between other site duties.
• Expense and receipt review. Reimbursements add documentation checks, policy checks, and sometimes resubmission.
• Multi-step approvals. A payment can pass through site operations, finance, and a sponsor or CRO approver.
• Payment-method failures. Incorrect account details, lost or inactive cards, unsupported methods, and regional limitations push payments into exception queues.
• Disconnected systems. The visit is already recorded in the clinical system, yet someone still has to tell the payment system it happened.

That last cause can amplify several of the others. When the clinical record and payment workflow are separate, every payment depends on a person noticing an event and repeating it elsewhere.

Every Payment Delay Becomes Site Work

A late payment becomes a question, and the question lands at the site. It travels from participant to coordinator, to payment administrator, to the payment platform, and back. The loop creates work nobody budgeted for: status calls and emails, missing-receipt investigations, card troubleshooting, reissues, and manual reconciliation when payment and study records disagree.

When staff administers participant payments by hand at the site, that work directly competes with research. The operational tradeoff is straightforward: a coordinator chasing a missing reimbursement is not scheduling visits or answering questions about side effects.

The same loop affects participants. Late payments do not explain every withdrawal. When participants are already covering study costs, a slow payment process adds pressure when continuing is hardest, making payment performance part of the participant experience.

“How Much?” Is Half the Payment Strategy

Compensation planning usually centers on how much participants should receive. A complete payment strategy asks five more questions.

How quickly do participants receive it? Track time from visit to usable funds, and from expense submission to reimbursement.

How predictable is it? A participant told that funds arrive within two business days of each visit can plan around it. A participant told “soon” cannot.

How much effort does it take? Count the forms, portals, receipt uploads, and follow-ups required to get paid.

Can participants use the money? Funds that arrive in a form the participant cannot easily spend have not finished their job.

What happens when something goes wrong? Decide before launch who resolves a failed payment, how quickly, and how the participant is told.

Participant Payment Methods and Choice

Participant payment methods commonly include reloadable physical cards, virtual cards, direct deposit, and, where necessary, checks.

No single method fits every participant. A virtual card suits someone who pays by phone. A participant without a bank account needs something other than direct deposit. Offering a choice, within what the protocol and IRB allow, removes one more reason the money is hard to use.

Global Trials Multiply Every Variable

A payment process that works at one U.S. site can break when a study adds countries. Each market brings its own variables:

• Local currencies and FX conversion
• Domestic banking systems and payment rails
• The payment methods participants actually use
• Tax treatment and reporting requirements
• Identity verification and data privacy rules
• Local rules on what can be reimbursed, and how
• Restrictions on certain payment types or recipients
• Language and localization of payment communications

In practice, a global sponsor runs a separate payment journey in every country, and a card program that serves U.S. participants well may have no equivalent elsewhere.

This is the problem modern payouts orchestration addresses: reaching local rails, currencies, and payout methods through one layer instead of building a separate payment arrangement for each country a study enters.

Automation Should Start Before Someone Clicks “Pay”

Many participant payment programs are digital only at the final step. A coordinator approves the payment, then the system sends it. The slowest part of the journey still waits on a person.

A more automated workflow runs differently. The participant completes an eligible activity, the clinical system records it, and the system triggers the applicable payment under rules configured in advance and consistent with the IRB-approved schedule.

The goal is to reduce the time between earning a payment and spending it. Faster money movement helps only after the payment is released.

Reimbursements that need receipt review will keep a human step, and exceptions will still need people. The aim is to spend staff time on decisions that require judgment and let recorded events trigger the rest.

Payout infrastructure is the last link in that chain. PayQuicker, a modern global payouts orchestration platform available in 210+ countries and territories, accepts payout instructions through a single API, batch file upload, or portal tools. A payment released by a sponsor’s trigger logic moves to delivery without rekeying, and participants can receive it by card, e-wallet, bank transfer, or a regional payout option.

Measure From Eligible Activity to Usable Funds

A report that says “payment delivered in 30 seconds” can hide a seven-day approval queue. The better metric runs the full journey: median time from eligible activity completed to usable funds received. Report it separately for compensation and reimbursement, and by country and payment method.

Supporting metrics:

• Median time from expense submission to reimbursement
• Percentage of payments delivered within the timeframe communicated to participants
• First-attempt payment success rate
• Payment exception rate and median time to resolve an exception
• Percentage of payments requiring manual intervention
• Participant payment inquiries per 100 visits
• Site staff hours spent administering participant payments
• Payment-method adoption by country
• Participant satisfaction with the payment experience

Manual intervention rate shows how much of the process depends on staff availability. Inquiries per 100 visits capture delays as participants feel them, a useful cross-check on the timing data.

Faster Payments Still Have to Be Compliant

Speed does not change the rules. A faster payment process still operates within:

• IRB-approved payment amounts and schedules
• Informed consent disclosures, which FDA says should set out “the amount and schedule of payment(s)”
• Proration, so participants who withdraw are paid for completed activities, as NIH guidance recommends
• Tax and reporting obligations in each jurisdiction
• Privacy protections for participant identity and health information
• Accurate payment records that reconcile to study data
• Safeguards against undue influence

Changes participants will notice, such as moving from an end-of-study payment to per-visit payments or adding a payment method, belong in the protocol and consent documents as well as in the payment configuration.

Audit One Real Participant Payment

Follow a single payment through your process. Pick a recent visit and answer these questions with timestamps rather than estimates:

1. When did the participant become eligible for payment?
2. When was eligibility recorded, and in which system?
3. When was the payment approved, and by whom?
4. How many people and systems touched it?
5. Was any data re-entered by hand?
6. When was the payment initiated?
7. When did the participant have usable funds?
8. Did the participant front any expenses, and for how long?
9. Could the participant check payment status without contacting the site?
10. If the payment had failed, who would have noticed, and how?
11. Who answers the participant’s question when they ask?
12. How much staff time did this one payment consume?

Then repeat the audit for a reimbursement, for a participant using a different payment method, and for a participant in another country. Comparing those four journeys shows where to start.

The Payment Experience Is Part of the Participant Experience

The payment process does not end when finance approves a payment or when a provider sends it. For the participant, it ends when the money is available to use.

That is why the right measure is the same one this article started with: time from eligible activity to usable funds. Everything in between, from verification and expense review to approval, initiation, and exception handling, is part of the participant payment experience.

When participants have already paid for gas, parking, meals, childcare, or travel, every additional day of reimbursement delay is another day they are financing the cost of participating in the study.

Sponsors and CROs already design protocols around participant burden. The payment workflow deserves the same scrutiny. Getting the amount right matters. Getting the money to the participant well matters too.

Book a demo to see how PayQuicker’s modern global payouts orchestration platform supports clinical trial participant payments at scale across countries, currencies, and payment methods.

FAQs

How fast should clinical trial participants be paid?

Sponsors should set a defined payment timeframe for each eligible activity and monitor whether they consistently meet it. The meaningful measure starts when the participant earns the payment, not when finance approves it.

Who should own participant payment exceptions?

Payment exceptions should have a designated owner and escalation process before enrollment begins. Site coordinators should not have to determine who handles failed transfers, lost cards, or incorrect payment details.

Can participant payments be automated from clinical trial systems?

Yes, eligible study activities can trigger payment workflows when clinical and payment systems are integrated. Activities requiring judgment, such as receipt review, may still require human approval.

Should every country use the same participant payment method?

No, payment methods should reflect local banking access, regulations, and participant preferences. A method that works well in one country may create access or usability problems in another.

What should sponsors require from a participant payment provider?

Sponsors should evaluate geographic coverage, payment methods, integration options, exception handling, reporting, and compliance support. They should also determine whether the provider can report the full time from payment authorization to when funds become available.